Last updated: May 26, 2026
Executive summary: NORPACE CR (disopyramide phosphate) is an older antiarrhythmic marketed in the U.S. as a sustained-release formulation. Public clinical-trial activity is limited, and the current market is driven mainly by legacy prescribing rather than large ongoing Phase 3 programs. From an IP and regulatory standpoint, near-term competitive pressure typically hinges on disopyramide generic entry, formulation patents (if any remain in force), and any Orange Book-listed exclusivities tied to the specific CR NDA. Without verified, current trial registries and FDA/NDA exclusivity records in the public domain, a precise, dated “clinical trials update” and a quantified revenue projection cannot be produced from reliable sources.
What is NORPACE CR (disopyramide phosphate) and how is it used clinically?
NORPACE CR is a sustained-release oral formulation of disopyramide phosphate, an IA antiarrhythmic drug used for suppression of ventricular arrhythmias in specific clinical contexts (historically, ventricular arrhythmias including those associated with structural heart disease).
Mechanism of action and dose form
- Active ingredient: disopyramide phosphate
- Dosage form: oral sustained-release (CR) tablets
- Therapeutic category: antiarrhythmic (class IA sodium-channel blocker)
Key safety and monitoring considerations that affect adoption
- Proarrhythmic risk and conduction abnormalities
- Anticholinergic effects
- ECG monitoring requirements
- Drug interactions that alter QT and conduction
What clinical trials have been run for NORPACE CR and what is the latest update?
Answer: No current, specific NORPACE CR drug-product Phase 2/3 trial pipeline update can be stated without verified, dated clinical registry entries tied explicitly to the NORPACE CR formulation (disopyramide phosphate CR). Publicly available trial activity for disopyramide as a molecule does not automatically translate to NORPACE CR as a branded CR product, and timelines depend on whether trials test immediate-release vs sustained-release, plus inclusion criteria and endpoints.
What to check to separate molecule-level from product-level trials
- ClinicalTrials.gov study terms including “NORPACE CR” or “disopyramide sustained release”
- NDA reference, formulation description, and dosing schedule
- Sponsor and trial locations (U.S. vs non-U.S. affects likely regulatory impact)
Why “trial activity” matters for near-term market outcomes
If no NORPACE CR-specific development is ongoing, future market dynamics rely more on:
- generic displacement timelines for disopyramide,
- any remaining branded formulation IP barriers,
- and changes in cardiology prescribing patterns for older antiarrhythmics.
What is the Orange Book status of NORPACE CR and what patents protect it?
Answer: A complete Orange Book-driven list of NORPACE CR patents and expiration dates cannot be produced here without verified Orange Book records tied to the exact NDA and dosage form “CR.”
What typically appears for branded CR antiarrhythmics
For many legacy CR products, the relevant exclusivity and patents often fall into buckets:
- composition-of-matter for disopyramide itself (less likely to survive decades-old filings),
- formulation and controlled-release composition/polymorphs,
- manufacturing and process patents,
- method-of-treatment patents (rare for older antiarrhythmics),
- FDA “marketing exclusivity” tied to a qualifying change (if any) for the specific NDA.
How patent estate strength is usually assessed
- Number of Orange Book-listed patents per NDA and per strength
- Claim scope around sustained-release matrix/coat technology
- Remaining regulatory exclusivity (5-year/7-year) if applicable to the CR product NDA
- Litigation history and consent decrees affecting launch timing
When does NORPACE CR lose exclusivity, and when can generics enter?
Answer: A specific “loss of exclusivity” date cannot be stated without the exact Orange Book listing and any applicable exclusivity periods tied to NORPACE CR’s NDA and label.
Entry pathways that determine launch timing
- ANDA for disopyramide CR strength(s)
- Paragraph IV challenges (if any Orange Book patents block generic entry)
- Carve-outs via “skinny labeling” if only certain indications are protected
- 505(b)(2) reformulations or alternative CR technologies (less common for legacy products)
What generic entry risks exist for NORPACE CR?
Answer: Generic entry risk for NORPACE CR depends on:
- whether the branded CR product is still the reference standard for controlled-release disopyramide in the specific strengths,
- and the existence of enforceable, formulation-specific Orange Book patents.
A generalized “low/high” risk statement cannot be made accurately without the actual remaining patent and exclusivity map for the NORPACE CR NDA.
What patent litigation affects NORPACE CR and disopyramide CR generics?
Answer: A litigation impact assessment (filed suits, PTAB outcomes, settlements, consent decrees) cannot be produced without verified dockets and case listings tied to NORPACE CR’s NDA and Orange Book patents.
What matters for investors and BD
- Whether any ANDA Paragraph IV suits were filed against the NORPACE CR NDA
- Whether settlements included “180-day exclusivity” triggers
- Whether design-around formulations were accepted as non-infringing
How does NORPACE CR compare with immediate-release disopyramide and other antiarrhythmics?
NORPACE CR differs from immediate-release disopyramide by sustained-release exposure profile, which can affect:
- dosing frequency,
- peak and trough concentrations,
- tolerability and ECG response patterns.
Competitive replacement dynamics
Even without direct product switching, clinicians may prefer newer classes depending on the arrhythmia profile, guideline evolution, and tolerability.
Which companies supply disopyramide and how is the competitive landscape shaping?
Answer: A named competitive landscape cannot be produced here without sourcing current U.S. market supply for disopyramide CR and immediate-release, including:
- branded holders,
- ANDA holders for CR and IR,
- and any authorized generics or distributor market structure.
Market analysis: How big is the NORPACE CR market today?
Answer: A quantified market size and share, plus price/mix trends, cannot be reliably produced here without verified commercial data (e.g., IQVIA/Drugstore-level NDC sales, prescriptions, wholesaler data) linked to NORPACE CR’s NDCs and strengths.
What drives sales for legacy antiarrhythmics
- Narrow patient populations with residual use cases
- Stability of cardiology prescribing habits in the short term
- Competition from generics on net price
- Hospital formulary decisions and payer coverage
Revenue projection: What does NORPACE CR revenue look like over the next 5 years?
Answer: A credible revenue projection requires current baseline sales and forward drivers (generic erosion, patent expiry, exclusivity, price changes). Those inputs cannot be provided accurately from reliable sourced data within this response.
What manufacturing or IP barriers could slow generic entry for NORPACE CR?
For controlled-release products, generic entry risk can be affected by:
- formulation reproducibility (release kinetics),
- process complexity,
- and patentable manufacturing details (if present in the Orange Book).
Without confirmed, in-force patents tied to NORPACE CR, a barrier analysis cannot be stated.
Key Takeaways
- NORPACE CR is a legacy sustained-release disopyramide brand; present market dynamics are primarily shaped by generic substitution and legacy prescribing patterns.
- A product-specific “clinical trials update” cannot be stated without verified, dated NORPACE CR-specific trial records.
- A product-specific IP and exclusivity timeline (Orange Book patents, expiration dates, exclusivity loss date) cannot be provided here without verified NDA and Orange Book listings tied to the NORPACE CR CR dosage form.
- A quantified market size and 5-year revenue projection cannot be produced without verified baseline commercial data and a confirmed exclusivity/patent map.
FAQs
1) Is NORPACE CR the only sustained-release disopyramide in the U.S.?
Not determinable here without current NDC-level supply mapping and label form comparison.
2) Do clinical trials for disopyramide automatically protect NORPACE CR?
No. Protection and exclusivity depend on the branded NDA and the formulation tested in qualifying trials.
3) Can generics launch before patent expiry using design-around formulations for disopyramide CR?
Yes in principle, but feasibility depends on Orange Book claim scope and infringement risk, which cannot be evaluated here without the patent list.
4) How do settlements in ANDA Paragraph IV cases typically affect NORPACE CR pricing and timing?
They can delay or accelerate launch via exclusivity and carve-outs, but specific outcomes require litigation docket details.
5) Does NORPACE CR have any biologic-style biosimilar competition?
No. It is a small-molecule antiarrhythmic; the relevant pathway is ANDA/generic substitution, not biosimilars.
References (APA)
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/
